ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Renal safety of amikacin compared with ceftriaxone in patients treated for urinary tract infection: an observational cohort study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAminoglycosides are broad-spectrum antibiotics commonly used as monotherapy for urinary tract infections (UTIs). However, their use is often limited by concerns regarding nephrotoxicity. We compared the renal safety of amikacin with ceftriaxone in patients treated for UTI with or without bloodstream infection.
methodsWe conducted a single-center retrospective cohort study including adult patients hospitalized between April 2018 and March 2022 who received amikacin or ceftriaxone for UTI for 3-10 days. Patients were matched 1:1 according to age, duration of therapy, and baseline renal function. The primary outcome was acute kidney injury (AKI), defined according to KDIGO criteria. Analyses included Kaplan-Meier time-to-event analysis, propensity score-adjusted Cox regression, and multivariable logistic regression. Alternative etiologies for AKI were also assessed.
resultsA total of 138 matched pairs were included. Overall, 15 patients (5.4%) developed AKI: 9 (6.5%) in the amikacin group and 6 (4.3%) in the ceftriaxone group (P = 0.597), and Kaplan-Meier analysis likewise showed no difference between groups (log-rank P = 0.962). In propensity score-adjusted analysis of the total cohort, amikacin was not associated with increased risk of AKI (aHR 1.305, 95% CI 0.448-3.802, P = 0.626). Independent risk factors for AKI included institutional residence, higher Charlson comorbidity index, and bloodstream infection. Most AKI cases were mild and had alternative explanations.
conclusionsIn this matched cohort, amikacin was not associated with a higher risk of AKI compared with ceftriaxone. These findings suggest that, in selected patients, amikacin may represent a safe carbapenem-sparing option. Further studies are needed to confirm these findings.
Indexed as
Identifiers
42560604What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.